mechanism of action of glp-1 receptor agonist Frontiers Mechanisms of Action and Therapeutic
Description
95% CI 1.021.74
A clinical trial in 2015 linked an undisclosed GLP-1 to significant improvements in OSA severity, while a 2016 clinical trial found that weight loss resulting from liraglutide was significantly associated with a reduction in the apnea-hypopnea index (AHI)
How Long Will Results Last
Restraints High Cost and Potential Gastrointestinal Side Effects May Restrain Market Growth The relatively high cost of GLP-1 receptor agonists can be a significant restraint on market growth, particularly in regions with limited healthcare access or reimbursement
The total dose remains the same, but the pharmacokinetic profile changes
Mfazo Hove
